Literature DB >> 2447993

The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig.

L Beijer1, J Botting, P Crook, A O Oyekan, C P Page, R Rylander.   

Abstract

1 Exposure of conscious guinea-pigs to an aerosol of endotoxin (25-100 micrograms ml-1) resulted in a dose-related, progressive accumulation of platelets in the thoracic region. Accumulation of 111indium oxine labelled erythrocytes was not observed following exposure to an aerosol of endotoxin (50 micrograms ml-1). 2 Pretreatment of guinea-pigs with the selective platelet activating factor (Paf)-antagonists. CV-3988 or brotizolam resulted in a dose-related inhibition of endotoxin-induced pulmonary platelet recruitment. Pretreatment of guinea-pigs with the selective Paf-antagonist BN 52021 resulted in significant inhibition of endotoxin-induced pulmonary platelet recruitment, although the effects of BN 52021 were not dose-related. 3 Pretreatment of guinea-pigs with indomethacin at doses known to inhibit cyclo-oxygenase did not inhibit endotoxin-induced pulmonary platelet recruitment, whereas higher doses of indomethacin produced a reduction in platelet recruitment in the lung. 4 Pretreatment of guinea-pigs with the anticoagulant heparin and the prostacyclin analogue ZK 36374 inhibited endotoxin-induced platelet recruitment. 5 These observations suggest that endotoxin-induced pulmonary platelet recruitment in the guinea-pig is secondary to the release of platelet activating factor, but not to cyclo-oxygenase products of arachidonic acid and may also involve activation of the coagulation cascade.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447993      PMCID: PMC1853711          DOI: 10.1111/j.1476-5381.1987.tb11384.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.

Authors:  D Nunez; M Chignard; R Korth; J P Le Couedic; X Norel; B Spinnewyn; P Braquet; J Benveniste
Journal:  Eur J Pharmacol       Date:  1986-04-16       Impact factor: 4.432

Review 2.  Inhibition of phospholipase.

Authors:  G J Blackwell; R J Flower
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

3.  Is platelet activating factor (PAF) a mediator of endotoxin shock?

Authors:  Z Terashita; Y Imura; K Nishikawa; S Sumida
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

4.  Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.

Authors:  D A Handley; R G Van Valen; M K Melden; S Flury; M L Lee; R N Saunders
Journal:  Immunopharmacology       Date:  1986-08

5.  Effect of endotoxin on airway responsiveness to aerosol histamine in sheep.

Authors:  A A Hutchison; J M Hinson; K L Brigham; J R Snapper
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-06

6.  Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor.

Authors:  G Camussi; I Pawlowski; C Tetta; C Roffinello; M Alberton; J Brentjens; G Andres
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

7.  Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity.

Authors:  J Casals-Stenzel; K H Weber
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

8.  Effects of dimethylsulfoxide (DMSO) on the oxygen paradox in perfused rat hearts.

Authors:  C E Ganote; M Sims; S Safavi
Journal:  Am J Pathol       Date:  1982-12       Impact factor: 4.307

9.  An in vivo model for studying platelet aggregation and disaggregation.

Authors:  C P Page; W Paul; J Morley
Journal:  Thromb Haemost       Date:  1982-06-28       Impact factor: 5.249

10.  Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man.

Authors:  F M Cuss; C M Dixon; P J Barnes
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

View more
  7 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 2.  Animal models for testing anti-inflammatory drugs for treatment of bronchial hyperreactivity in asthma.

Authors:  M J Linssen; O H Wilhelms; H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1991-12-13

3.  Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

Authors:  F Lopez Diez; M L Nieto; S Fernandez-Gallardo; M A Gijon; M Sanchez Crespo
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 4.  Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists.

Authors:  H O Heuer
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice.

Authors:  Haiya Wu; Jun Yang; Emily M Su; Ling Li; Caiqi Zhao; Xi Yang; Zhaowei Gao; Mengyao Pan; Peiyu Sun; Wei Sun; Yiyi Jiang; Xiao Su
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

6.  Important role of platelets in modulating endotoxin-induced lung inflammation in CFTR-deficient mice.

Authors:  Caiqi Zhao; Emily M Su; Xi Yang; Zhaowei Gao; Ling Li; Haiya Wu; Yiyi Jiang; Xiao Su
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

7.  Serum cytokines and clinical features in patients with fever and thrombocytopenia syndrome.

Authors:  Huanzhu Chen; Chun Lin; Zhiqiang Fan; Wenjun Yu; Manxiong Cao; Changwen Ke; Xiaoyang Jiao
Journal:  Clin Chim Acta       Date:  2019-03-01       Impact factor: 3.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.